JPWO2023114944A5 - - Google Patents

Info

Publication number
JPWO2023114944A5
JPWO2023114944A5 JP2024535950A JP2024535950A JPWO2023114944A5 JP WO2023114944 A5 JPWO2023114944 A5 JP WO2023114944A5 JP 2024535950 A JP2024535950 A JP 2024535950A JP 2024535950 A JP2024535950 A JP 2024535950A JP WO2023114944 A5 JPWO2023114944 A5 JP WO2023114944A5
Authority
JP
Japan
Prior art keywords
fluoroalkyl
compound
branched
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024535950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546950A (ja
JP2024546950A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081714 external-priority patent/WO2023114944A1/en
Publication of JP2024546950A publication Critical patent/JP2024546950A/ja
Publication of JP2024546950A5 publication Critical patent/JP2024546950A5/ja
Publication of JPWO2023114944A5 publication Critical patent/JPWO2023114944A5/ja
Pending legal-status Critical Current

Links

JP2024535950A 2021-12-16 2022-12-15 脂質ナノ粒子に用いるフッ化カチオン性脂質 Pending JP2024546950A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290384P 2021-12-16 2021-12-16
US63/290,384 2021-12-16
PCT/US2022/081714 WO2023114944A1 (en) 2021-12-16 2022-12-15 Fluorinated cationic lipids for use in lipid nanoparticles

Publications (3)

Publication Number Publication Date
JP2024546950A JP2024546950A (ja) 2024-12-26
JP2024546950A5 JP2024546950A5 (https=) 2025-12-12
JPWO2023114944A5 true JPWO2023114944A5 (https=) 2025-12-12

Family

ID=85108851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024535950A Pending JP2024546950A (ja) 2021-12-16 2022-12-15 脂質ナノ粒子に用いるフッ化カチオン性脂質

Country Status (11)

Country Link
US (1) US20250092002A1 (https=)
EP (2) EP4700017A2 (https=)
JP (1) JP2024546950A (https=)
KR (1) KR20240124983A (https=)
CN (1) CN118647601A (https=)
CA (1) CA3242406A1 (https=)
DK (1) DK4448486T3 (https=)
ES (1) ES3058144T3 (https=)
FI (1) FI4448486T3 (https=)
IL (1) IL313487A (https=)
WO (1) WO2023114944A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250161227A1 (en) 2023-11-17 2025-05-22 Acuitas Therapeutics, Inc. Pegylated lipids
WO2025128696A1 (en) 2023-12-12 2025-06-19 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025132122A1 (en) 2023-12-13 2025-06-26 Berlin Institute Of Health Methods of delivering therapeutics using lipid nanoparticles
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025166323A2 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. Crispr-related methods and compositions targeting lipoprotein (a) expression
WO2025174858A1 (en) 2024-02-15 2025-08-21 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
TW202543583A (zh) 2024-03-01 2025-11-16 加拿大商阿奎特斯醫療公司 用於將治療劑包覆於脂質奈米顆粒中之材料及方法
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
WO2025189064A1 (en) 2024-03-08 2025-09-12 Genzyme Corporation Lipid nanoparticles
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
TW202602839A (zh) 2024-04-10 2026-01-16 加拿大商阿奎特斯醫療公司 用於脂質奈米顆粒之陽離子脂質化合物
WO2025231114A1 (en) 2024-05-01 2025-11-06 Acuitas Therapeutics, Inc. Method of using lipid nanoparticles for intramuscular delivery
WO2025240833A1 (en) 2024-05-17 2025-11-20 Acuitas Therapeutics, Inc. Galnac lipid compounds for use in lipid nanoparticles
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
SMT202200502T1 (it) 2014-06-25 2023-01-13 Acuitas Therapeutics Inc Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
LT3313829T (lt) * 2015-06-29 2024-08-12 Acuitas Therapeutics Inc. Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
EP3668834B1 (en) * 2017-08-17 2024-10-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US20200093936A1 (en) * 2018-09-21 2020-03-26 The Trustees Of The University Of Pennsylvania Therapeutic Targeting of Lipid Nanoparticles

Similar Documents

Publication Publication Date Title
JPWO2023114944A5 (https=)
JPWO2023114943A5 (https=)
JP2020517694A5 (https=)
US5567765A (en) Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of use
JPWO2021000041A5 (https=)
JP2018533573A5 (https=)
US4684633A (en) Phospholipid-emulsified prostaglandin composition
JP2018521052A5 (https=)
JPWO2020252589A5 (https=)
JP3631755B2 (ja) ポリオキシエチレン含有脂質二本鎖誘導体
Riess et al. Advanced fluorocarbon-based systems for oxygen and drug delivery, and diagnosis
JP2006528701A5 (https=)
JP2004508292A5 (https=)
JP2013056948A (ja) 安定なプロスタグランジン含有組成物
JPWO2022016070A5 (https=)
JPWO1995025764A1 (ja) ポリオキシエチレン含有脂質二本鎖誘導体
JPWO2023114937A5 (https=)
CN101579314A (zh) 有机-无机复合脂质体的抗癌药物缓释制剂及其制备方法
JPH03204853A (ja) プロスタグランジン類縁体およびその脂肪乳剤
KR20160127828A (ko) 면역원성 리포솜 제형
JP2011513317A5 (https=)
MX2008001350A (es) Composiciones y metodos para emulsificar un perfluorocarbono con un agente tensioactivo portador de oxigeno.
EP0758645B1 (en) Prostaglandin derivatives
JPH0625017A (ja) X線造影製剤類及びgi管の透視におけるそれらの使用方法
EP0841896B1 (en) Reverse gels comprising a continuous fluorinated phase